Oral Biolife Inc.

Oral Biolife Inc. , based in the US, specializes in developing innovative dental solutions, particularly focusing on treatments for periodontal disease through advanced biotechnology applications. Founded in 2022 and headquartered in Bethlehem, US, Oral Biolife Inc. focuses on creating biotechnological solutions for dental health.

The company has reportedly engaged in one deal as of October 15, 2025. Oral Biolife's primary product is Ambrilux Dental Gel, a revolutionary solution designed for the treatment of periodontal disease by regenerating bone tissue lost due to this condition. The gel is applied directly into the periodontal pocket using standard dental tools, ensuring precise and effective treatment without the need for invasive procedures such as bone grafts or complex surgeries. This innovative technology not only provides structural integrity to the affected area but also promotes natural tissue repair, making it a significant advancement in dental health care.

Ambrilux Dental Gel is aimed at both human patients and the veterinary market, having recently been licensed to a leading global animal health pharmaceutical organization for commercialization in veterinary applications. The geographical markets for these products include North America and Europe, where the dental health needs of both human and animal patients are being addressed through this cutting-edge technology. Oral Biolife's revenue model is centered around the commercialization of its flagship product, Ambrilux Dental Gel, through strategic partnerships and licensing agreements. The company has successfully entered into a partnership with a top-tier animal health pharmaceutical organization, indicating a B2B transaction structure that facilitates the distribution of the product within the veterinary market.

These transactions typically involve the licensing of the Ambrilux Dental Gel formulation, allowing the partner to market and sell the product in their established networks. While specific pricing plans for the Ambrilux Dental Gel are not disclosed, the company's strategy appears to focus on maximizing value through these commercial partnerships, enhancing accessibility to innovative treatment options for periodontal disease in both humans and animals. This approach positions Oral Biolife to transition into a revenue-generating, commercial-stage entity as it continues to expand its reach and impact in the dental healthcare sector. In October 2025, Oral Biolife Inc.

raised an undisclosed amount of venture funding from other unspecified investors. The company plans to utilize this funding to expand preclinical and clinical programs and scale up manufacturing while supporting market awareness for nearly 17 million people over age 30 at risk for periodontal disease. Additionally, Oral Biolife aims to introduce new products designed for both human and veterinary applications, focusing on expanding its reach into North America and Europe, with specific timelines and product details to be announced in the upcoming quarters.